Covered recipient · General Payments record
CURTIS J DUNSHEE
Allopathic & Osteopathic Physicians Urology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$4,677.56
52 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Honoraria | $2,590.00 | 2 |
| Consulting Fee | $1,100.00 | 1 |
| Food and Beverage | $728.82 | 43 |
| Education | $258.74 | 6 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $2,709.56 | 12 |
| Janssen Scientific Affairs, LLC | $1,100.00 | 1 |
| Astellas Pharma US Inc | $277.55 | 10 |
| AstraZeneca Pharmaceuticals LP | $132.88 | 1 |
| Dendreon Pharmaceuticals LLC | $93.40 | 5 |
| Myovant Sciences Inc. | $81.02 | 5 |
| Endo Pharmaceuticals Inc. | $79.89 | 5 |
| COLOPLAST CORP | $51.50 | 3 |
| BOSTON SCIENTIFIC CORPORATION | $37.61 | 3 |
| Teleflex LLC | $29.16 | 2 |
| 180 Medical, Inc. | $20.41 | 1 |
| Amgen Inc. | $20.34 | 1 |
| UROVANT SCIENCES INC | $15.26 | 1 |
| AbbVie Inc. | $14.89 | 1 |
| Allergan, Inc. | $14.09 | 1 |
Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CURTIS J DUNSHEE
NPI 1538161880 · CMS profile ID 296524
Allopathic & Osteopathic Physicians / Urology
TUCSON, AZ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1538161880?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CURTIS J DUNSHEE, NPI 1538161880, CMS profile ID 296524. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538161880?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). CURTIS J DUNSHEE, NPI 1538161880, CMS profile ID 296524. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538161880?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- CURTIS J DUNSHEE, NPI 1538161880, CMS profile ID 296524, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–52 of 52 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1538161880?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
52 matching records · $4,677.56 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–52 of 52.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AbbVie Inc. | $14.89 | 02/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794386981 | CMS |
| Endo Pharmaceuticals Inc. | $16.02 | 01/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 828728803 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $21,510.00 | 15 |
| PY2025 | Principal investigator | $1,386,082.00 | 101 |
| PY2024 | Recipient | $18,950.00 | 12 |
| PY2024 | Principal investigator | $2,378,147.02 | 164 |
| PY2023 | Recipient | $25,230.00 | 21 |
| PY2023 | Principal investigator | $1,949,173.64 | 144 |
| PY2022 | Recipient | $3,200.00 | 1 |
| PY2022 | Principal investigator | $2,429,227.31 | 214 |
| PY2021 | Recipient | $5,066.33 | 4 |
| PY2021 | Principal investigator | $2,777,315.99 | 159 |
| PY2020 | Recipient | $4,330.00 | 5 |
| PY2020 | Principal investigator | $3,054,970.61 | 180 |
| PY2019 | Recipient | $7,386.09 | 20 |
| PY2019 | Principal investigator | $1,959,773.49 | 164 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
116 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $640.90 | 12/16/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228747464 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $300.00 | 12/03/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892665 |
| Principal investigator 1 | PFIZER INC. | $2,500.00 | 11/26/2025 | Non-covered Recipient Entity Arizona Urology Specialists PLLC AUS Research | A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER MEVPRO2 | No dispute reported | 06/30/2026 | 1228729268 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 11/19/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726308 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 11/18/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726306 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 11/10/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727835 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 11/08/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228719871 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $750.00 | 11/06/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892581 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $40.00 | 11/05/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176654634 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $40.00 | 11/05/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176654682 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $800.00 | 11/05/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176654815 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,161.00 | 11/05/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176654824 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $40.00 | 11/05/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176654853 |
| Recipient | PFIZER INC. | $330.00 | 11/03/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727343 |
| Principal investigator 1 | PFIZER INC. | $18,918.00 | 10/25/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228742263 |
| Principal investigator 1 | Janssen Research & Development, LLC | $252.00 | 09/05/2025 | Non-covered Recipient Entity Urological Associates Of Sthrn Arizona PC Admin Ofc | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175166867 |
| Principal investigator 1 | Astellas Pharma Global Development | $400.00 | 09/04/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1234181806 |
| Principal investigator 1 | PFIZER INC. | $92,415.77 | 08/21/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726324 |
| Principal investigator 1 | PFIZER INC. | $92,415.77 | 08/20/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726394 |
| Principal investigator 1 | Janssen Research & Development, LLC | $475.00 | 08/18/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175345364 |
| Principal investigator 1 | PFIZER INC. | $101.00 | 08/09/2025 | Non-covered Recipient Entity Arizona Urology Specialists PLLC AUS Research | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228786531 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,000.00 | 08/08/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892381 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,000.00 | 08/08/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892384 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,250.00 | 08/04/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175345401 |
| Principal investigator 1 | PFIZER INC. | $1,193.00 | 07/25/2025 | Non-covered Recipient Entity Arizona Urology Specialists PLLC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228773528 |
| Principal investigator 1 | PFIZER INC. | $5,574.35 | 07/11/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228782082 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $40.00 | 07/09/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176640476 |
| Principal investigator 1 | PFIZER INC. | $101.00 | 07/01/2025 | Non-covered Recipient Entity Arizona Urology Specialists PLLC AUS Research | A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER MEVPRO2 | No dispute reported | 06/30/2026 | 1228764749 |
| Principal investigator 1 | PFIZER INC. | $2,047.50 | 06/26/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228720425 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,284.00 | 06/23/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175345335 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,284.00 | 06/23/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175345389 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14,541.00 | 06/18/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176636377 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $580.50 | 06/18/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176636382 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $11,601.60 | 06/18/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176636386 |
| Recipient | PFIZER INC. | $940.00 | 06/14/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228724344 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,138.00 | 06/09/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175345341 |
| Recipient | Dendreon Pharmaceuticals LLC | $9,750.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891311 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $9,750.00 | 06/05/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS | ProvONE | No dispute reported | 06/30/2026 | 1247891970 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $9,626.00 | 06/05/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY | ProvONE | No dispute reported | 06/30/2026 | 1247892160 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,984.00 | 06/02/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175345425 |
| Principal investigator 1 | MEDIVATION LLC. | $1,628.90 | 06/02/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228780538 |
| Principal investigator 1 | MEDIVATION LLC. | $1,628.90 | 06/02/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790200 |
| Principal investigator 1 | MEDIVATION LLC. | $325.00 | 06/02/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791983 |
| Principal investigator 1 | MEDIVATION LLC. | $325.00 | 06/02/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792101 |
| Principal investigator 1 | MEDIVATION LLC. | $325.00 | 06/02/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792593 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 06/02/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752859 |
| Recipient | PFIZER INC. | $940.00 | 06/02/2025 | Covered Recipient Physician | PF06821497 CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228771253 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 06/01/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752325 |
| Recipient | PFIZER INC. | $940.00 | 05/31/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228752898 |
| Recipient | PFIZER INC. | $940.00 | 05/31/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228768730 |
| Principal investigator 1 | Janssen Research & Development, LLC | $350.00 | 05/29/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175345306 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 05/27/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753837 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,277.00 | 05/23/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175345372 |
| Principal investigator 1 | PFIZER INC. | $1,592.50 | 05/23/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228772318 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 05/22/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753139 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,269.00 | 05/19/2025 | Non-covered Recipient Entity Arizona Uro Specialists Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175164781 |
| Principal investigator 1 | Janssen Research & Development, LLC | $252.00 | 05/16/2025 | Non-covered Recipient Entity Urological Associates Of Sthrn Arizona PC Admin Of | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175166876 |
| Principal investigator 1 | PFIZER INC. | $11,147.50 | 05/14/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228772478 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 05/08/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALIST | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228763239 |
| Principal investigator 1 | MEDIVATION LLC. | $325.00 | 05/05/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790439 |
| Principal investigator 1 | MEDIVATION LLC. | $1,628.90 | 05/05/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791666 |
| Principal investigator 1 | MEDIVATION LLC. | $698.75 | 05/05/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792167 |
| Recipient | PFIZER INC. | $330.00 | 05/01/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228771496 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,630.41 | 04/30/2025 | Non-covered Recipient Entity HIGHLAND MEDICAL HEMATOLOGY AND ONCOLOGY | A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1185539551 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,569.00 | 04/28/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175345275 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,688.00 | 04/24/2025 | Non-covered Recipient Entity Arizona Uro Specialists Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175164797 |
| Principal investigator 1 | PFIZER INC. | $2,434.70 | 04/24/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228797243 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,200.00 | 04/23/2025 | Non-covered Recipient Entity HIGHLAND MEDICAL HEMATOLOGY AND ONCOLOGY | A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib Abiraterone Versus Placebo Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) | No dispute reported | 06/30/2026 | 1185539557 |
| Recipient | PFIZER INC. | $330.00 | 04/18/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228767513 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,192.25 | 04/09/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176632523 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $11,965.50 | 04/09/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176632780 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,000.00 | 04/09/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176632835 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $875.00 | 04/09/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176632838 |
| Principal investigator 1 | PFIZER INC. | $64,203.40 | 04/08/2025 | Non-covered Recipient Entity Arizona Urology Specialists PLLC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228779520 |
| Principal investigator 1 | PFIZER INC. | $47,619.28 | 04/08/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228780316 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,284.00 | 04/03/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175345348 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $14,875.32 | 04/02/2025 | Non-covered Recipient Entity HIGHLAND MEDICAL HEMATOLOGY AND ONCOLOGY | A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 | No dispute reported | 06/30/2026 | 1185539553 |
| Principal investigator 1 | MEDIVATION LLC. | $1,628.90 | 04/01/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792918 |
| Recipient | PFIZER INC. | $3,200.00 | 03/27/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228770806 |
| Principal investigator 1 | MEDIVATION LLC. | $8,060.00 | 03/21/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775737 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,000.00 | 03/19/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1234181804 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,688.00 | 03/17/2025 | Non-covered Recipient Entity Arizona Uro Specialists Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175164789 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 03/14/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752329 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 03/13/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754222 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,138.00 | 03/07/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175345297 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 03/04/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754218 |
| Principal investigator 1 | MEDIVATION LLC. | $325.00 | 03/03/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774356 |
| Principal investigator 1 | MEDIVATION LLC. | $698.75 | 03/03/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774373 |
| Principal investigator 1 | MEDIVATION LLC. | $325.00 | 03/03/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774645 |
| Principal investigator 1 | MEDIVATION LLC. | $325.00 | 03/03/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774843 |
| Principal investigator 1 | MEDIVATION LLC. | $325.00 | 03/03/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776359 |
| Principal investigator 1 | MEDIVATION LLC. | $325.00 | 03/03/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776541 |
| Principal investigator 1 | MEDIVATION LLC. | $698.75 | 03/03/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228777735 |
| Principal investigator 1 | MEDIVATION LLC. | $325.00 | 03/03/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228778577 |
| Principal investigator 1 | MEDIVATION LLC. | $325.00 | 03/03/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228786553 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 03/03/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228751917 |
| Principal investigator 1 | Janssen Research & Development, LLC | $27,846.00 | 02/21/2025 | Non-covered Recipient Entity Arizona Uro Specialists Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175164774 |
| Principal investigator 1 | PFIZER INC. | $9,169.59 | 02/14/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228760974 |
| Recipient | PFIZER INC. | $940.00 | 02/13/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228759663 |
| Recipient | PFIZER INC. | $940.00 | 02/13/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228770593 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,188.00 | 02/10/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175345407 |
| Principal investigator 1 | Janssen Research & Development, LLC | $350.00 | 02/07/2025 | Non-covered Recipient Entity Arizona Uro Specialists Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175164764 |
| Principal investigator 1 | Janssen Research & Development, LLC | $112.00 | 02/03/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175345319 |
| Principal investigator 1 | Janssen Research & Development, LLC | $475.00 | 02/03/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175345381 |
| Recipient | PFIZER INC. | $940.00 | 02/03/2025 | Covered Recipient Physician | PF06821497 CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228759635 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $41,276.44 | 01/29/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS | A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 | No dispute reported | 06/30/2026 | 1185539555 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | PF06821497 CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228723488 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228760331 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228760650 |
| Principal investigator 1 | PFIZER INC. | $1,755.00 | 01/25/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228798510 |
| Principal investigator 1 | PFIZER INC. | $15,036.00 | 01/24/2025 | Non-covered Recipient Entity Arizona Urology Specialists PLLC AUS Research | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228801655 |
| Principal investigator 1 | Janssen Research & Development, LLC | $252.00 | 01/10/2025 | Non-covered Recipient Entity Urological Associates Of Sthrn Arizona PC Admin Of | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175167183 |
| Principal investigator 1 | PFIZER INC. | $184,831.55 | 01/10/2025 | Non-covered Recipient Entity Urological Associates of Southern Arizona PC | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228762259 |
| Principal investigator 1 | MEDIVATION LLC. | $1,628.90 | 01/02/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775926 |
| Principal investigator 1 | MEDIVATION LLC. | $8,060.00 | 01/02/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228785609 |
| Principal investigator 1 | MEDIVATION LLC. | $1,628.90 | 01/02/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS PLLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228785612 |